Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-06-01

Clinical Trial Update: The Feasibility of Florbetapir Quantitation [Phase 4]

View source ↗

Summary

A Phase 4 trial update assessing the feasibility of quantifying florbetapir for PET imaging in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMYVID (Florbetapir F-18)

Snippet

Sponsor: Avid Radiopharmaceuticals | Conditions: Alzheimers Disease | Phase 4 | Status: COMPLETED | Results posted: 2015-06-01